RMP-7: Began a third Phase II trial in up to 90 patients, measuring time to tumor progression and deterioration in clinical status, compared to treatment with c

By WIR Staff | Mar 27, 1995 | 8:00 AM GMT

Alkermes Inc. (ALKS), Cambridge, Mass.

Read the full 57 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

Article Purchase

This article may not be distributed to non-subscribers

More Info >PURCHASE